

DAFTAR PUSTAKA

- Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., ... Ribas, A. (2014). Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. *Clinical Cancer Research*, 20(13), 3446–3457. <https://doi.org/10.1158/1078-0432.CCR-13-2797>
- Bryan, L. J., & Gordon, L. I. (2015). Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. *Blood Reviews*, 29(1), 25–32. <https://doi.org/10.1016/j.blre.2014.09.004>
- Camicia, R., Winkler, H. C., & Hassa, P. O. (2015). *Novel drug targets for personalized precision medicine in relapsed / refractory diffuse large B-cell lymphoma : a comprehensive review*. *Molecular Cancer*. Molecular Cancer. <https://doi.org/10.1186/s12943-015-0474-2>
- Chan, W. J. C. (2010). Pathogenesis of diffuse large B cell lymphoma, 219–230. <https://doi.org/10.1007/s12185-010-0602-0>
- Chemotherapy, C., Rituximab, P., With, C., Aloneelderly, C., With, P., & Lymphoma, D. L. (2002). CHOP PLUS RITUXIMAB VS . CHOP ALONE IN ELDERLY PATIENTS WITH DIFFUSE LARGE-B-CELL LYMPHOMA A CHOP CHEMOTHERAPY PLUS RITUXIMAB COMPARED WITH CHOP ALONE IN ELDERLY PATIENTS WITH DIFFUSE LARGE-B-CELL LYMPHOMA, 346(4), 235–242.
- Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., ... Rodig, S. J. (2013). PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. *Clinical Cancer Research*, 19(13), 3462–3473. <https://doi.org/10.1158/1078-0432.CCR-13-0855>
- Chen, Y., Han, T., Iqbal, J., Irons, R., Chan, W. C., Zhu, X., & Fu, K. (2010). Diffuse large B-cell lymphoma in Chinese patients. *American Journal of Clinical Pathology*, 133(2), 305–313. <https://doi.org/10.1309/AJCP4H6ADGYDZMOA>
- Dayang Sharyati Datu Abdul, S., Teoh, S.-H., Peh, S.-C., & Cheah, S.-C. (2020). Retrospective Lymphoma Study from Malaysia Private Hospital. *International Journal of Cancer and Clinical Research*, 7(4), 1–8. <https://doi.org/10.23937/2378-3419/1410140>
- De Paepe, P., Achten, R., Verhoef, G., Wlodarska, I., Stul, M., Vanhentenrijk, V., ... De Wolf-Peeters, C. (2005). Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. *Journal of Clinical Oncology*, 23(28), 7060–7068. <https://doi.org/10.1200/JCO.2005.15.503>
- Denman, A. M. (1992). *Cellular and Molecular Immunology*. *Postgraduate Medical Journal* (Vol. 68). <https://doi.org/10.1136/pgmj.68.798.305>
- Ding, W., LaPlant, B. R., Call, T. G., Parikh, S. A., Leis, J. F., He, R., ... Ansell, S. M. (2017). Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood*, 129(26), 3419–3427. <https://doi.org/10.1182/blood-2017-02-765685>
- Dobashi, A. (2016). Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. *Journal of Clinical and Experimental Hematopathology : JCEH*, 56(2), 71–78.

<https://doi.org/10.3960/jslrr.56.71>

- Dong, L., Lv, H., Li, W., Song, Z., Li, L., Zhou, S., ... Zhang, H. (2016). Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. *Oncotarget*, 7(22), 33350–33362. <https://doi.org/10.18632/oncotarget.9061>
- Dong, Y., Sun, Q., & Zhang, X. (2017). PD-1 and its ligands are important immune checkpoints in cancer, 8(2), 2171–2186.
- Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. *Nature Immunology*, 3(11), 991–998. <https://doi.org/10.1038/ni1102-991>
- Fang, X., Xiu, B., Yang, Z., Qiu, W., Zhang, L., Zhang, S., ... Zeng, Y. (2017). The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. *Medicine (United States)*, 96(15), 1–7. <https://doi.org/10.1097/MD.0000000000006398>
- García, A., Recondo, G., Greco, M., de la Vega, M., Perazzo, F., Avagnina, A., & Denninghoff, V. (2020). Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. *Heliyon*, 6(6), 4–7. <https://doi.org/10.1016/j.heliyon.2020.e04117>
- Georgiou, K., Chen, L., Berglund, M., Ren, W., Miranda, N. F. C. C. De, Lisboa, S., ... Panhammarstr, Q. (2016). Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas, 127(24), 3026–3035. <https://doi.org/10.1182/blood-2015-12-686550>.The
- Gravelle, P., Burrioni, B., & Péricart, S. (2017). Mechanisms of PD-1 / PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma : a summary of immunohistochemical studies, 8(27), 44960–44975.
- Gupta, M., Han, J. J., Stenson, M., Maurer, M., Wellik, L., Hu, G., ... Witzig, T. E. (2012). Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation. *Blood*, 119(12), 2844–2853. <https://doi.org/10.1182/blood-2011-10-388538>
- He, B., Yan, F., & Wu, C. (2018). Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. *Biomedicine and Pharmacotherapy*, 98(November 2017), 95–101. <https://doi.org/10.1016/j.biopha.2017.11.146>
- Honda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014). Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues. *Immunity*, 40(2), 235–247. <https://doi.org/10.1016/j.immuni.2013.11.017>
- Huang, S., Nong, L., Liang, L., Zheng, Y., Wang, W., Liu, J., ... Li, T. (2019). Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma. *Cancer Medicine*, 8(8), 3831–3845. <https://doi.org/10.1002/cam4.2316>
- Huh, J. (2012). Epidemiologic overview of malignant lymphoma. *The Korean Journal of Hematology*, 47(2), 92. <https://doi.org/10.5045/kjh.2012.47.2.92>
- Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., ... Zeng, Z. (2019). Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. *Molecular*

- Cancer*, 18(1), 1–17. <https://doi.org/10.1186/s12943-018-0928-4>
- Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali, M. A. A., ... Wherry, E. J. (2011). Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. *Nature Immunology*, 12(7), 663–671. <https://doi.org/10.1038/ni.2046>
- Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008). PD-1 and Its Ligands in Tolerance and Immunity. *Annual Review of Immunology*, 26(1), 677–704. <https://doi.org/10.1146/annurev.immunol.26.021607.090331>
- Kumar, V., Abbas, A., & Aster, J. (n.d.). Robbins Basic Pathology- ClinicalKey. Retrieved from <https://www-clinicalkey-es.ezproxy.javeriana.edu.co/#!/browse/book/3-s2.0-C20140017194>
- Laurent, C., Fabiani, B., Do, C., Tchernonog, E., Cartron, G., Gravelle, P., ... Coppo, P. (2016). Immune-checkpoint expression in epstein-barr virus positive and negative plasmablastic lymphoma: A clinical and pathological study in 82 patients. *Haematologica*, 101(8), 976–983. <https://doi.org/10.3324/haematol.2016.141978>
- Lenz, G., & Staudt, L. M. (2010). Aggressive lymphomas. *New England Journal of Medicine*, 362(15), 1417–1429. <https://doi.org/10.1056/NEJMra0807082>
- Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., ... Timmerman, J. (2016). Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. *Journal of Clinical Oncology*, 34(23), 2698–2704. <https://doi.org/10.1200/JCO.2015.65.9789>
- Liu, X. J., & Guan, Q. L. (2020). Mechanisms of resistance to immune checkpoint inhibitors. *World Chinese Journal of Digestology*, 28(17), 857–864. <https://doi.org/10.11569/wcjd.v28.i17.857>
- Mescher, A. L. (1800). *Basic Histology Junqueira*.
- Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014). ScienceDirect New insights into cancer immunoediting and its three component phases — elimination , equilibrium and escape. *Current Opinion in Immunology*, 27, 16–25. <https://doi.org/10.1016/j.coi.2014.01.004>
- Msandiwa, R., Hausler, H., Ph, D., Ram, M., Ph, D., McIntyre, J. A., ... Luceri, R. M. (2005). new england journal. SCD-Heft. *Heart Failure*, 225–237.
- Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K. H., ... Staudt, L. M. (2011). Oncogenically active MYD88 mutations in human lymphoma. *Nature*, 470(7332), 115–121. <https://doi.org/10.1038/nature09671>
- Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R. S. K., Küppers, R., & Dalla-Favera, R. (2001). Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature*, 412(6844), 341–346. <https://doi.org/10.1038/35085588>
- Patsoukis, N., Sari, D., & Boussiotis, V. A. (2012). PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. *Cell Cycle*, 11(23), 4305–4309. <https://doi.org/10.4161/cc.22135>
- Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., Silverman, G. J., & Mor, A. (2014). Programmed death-1 pathway in cancer and autoimmunity. *Clinical Immunology*,

153(1), 145–152. <https://doi.org/10.1016/j.clim.2014.04.010>

- Peled, J. U., Kuang, F. L., Iglesias-Ussel, M. D., Roa, S., Kalis, S. L., Goodman, M. F., & Scharff, M. D. (2008). The Biochemistry of Somatic Hypermutation. *Annual Review of Immunology*, 26(1), 481–511.
<https://doi.org/10.1146/annurev.immunol.26.021607.090236>
- Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015). Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. *Applied Immunohistochemistry and Molecular Morphology*, 23(8), 541–549. <https://doi.org/10.1097/PAI.0000000000000256>
- Qiu, L., Zheng, H., & Zhao, X. (2019). The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: A meta-analysis. *BMC Cancer*, 19(1), 1–12. <https://doi.org/10.1186/s12885-019-5466-y>
- Qiu, Y., Jiang, J., Zhang, M., & Qin, Y. (2019). Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. *Oncology Letters*, 18(1), 161–168.
<https://doi.org/10.3892/ol.2019.10302>
- RI, S. W. P. (2017). No Title. [زید رزم ینی آب های . □ □ □ □ □ .](https://doi.org/10.1016/j.clim.2014.04.010)
- Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., ... Daud, A. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. *The Lancet*, 384(9948), 1109–1117. [https://doi.org/10.1016/S0140-6736\(14\)60958-2](https://doi.org/10.1016/S0140-6736(14)60958-2)
- Rodriguez-Justo, M., & Marafioti, T. (2015). Diffuse large B-cell lymphoma and Burkitt lymphoma. *Diagnostic Histopathology*, 21(10), 391–399.
<https://doi.org/10.1016/j.mpdhp.2015.09.004>
- Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., ... Staudt, L. M. (2003). Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *Journal of Experimental Medicine*, 198(6), 851–862.
<https://doi.org/10.1084/jem.20031074>
- Savage, K. J., Monti, S., Kutok, J. L., Cattoretti, G., Neuberg, D., De Leval, L., ... Shipp, M. A. (2003). The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood*, 102(12), 3871–3879. <https://doi.org/10.1182/blood-2003-06-1841>
- Shi, Y., Han, Y., Yang, J., Liu, P., He, X., Zhang, C., ... Sun, Y. (2019). Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. *Chinese Journal of Cancer Research*, 31(1), 152–161.
<https://doi.org/10.21147/j.issn.1000-9604.2019.01.10>
- Shiozawa, E., Yamochi-Onizuka, T., Takimoto, M., & Ota, H. (2007). The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. *Leukemia Research*, 31(11), 1579–1583. <https://doi.org/10.1016/j.leukres.2007.03.017>

- Siegel, R. L., & Miller, K. D. (2019). Cancer Statistics , 2019, 69(1), 7–34.
<https://doi.org/10.3322/caac.21551>
- Škunca, Ž. (2020). B Cell Lymphomagenesis. *Normal and Malignant B-Cell*, 1–17.
<https://doi.org/10.5772/intechopen.87241>
- Snak, Y., Indrawati, Widayati, K., Arfian, N., & Anggorowati, N. (2018). Molecular subtypes, apoptosis and proliferation status in Indonesian diffuse large B-cell lymphoma cases. *Asian Pacific Journal of Cancer Prevention*, 19(1), 185–191.
<https://doi.org/10.22034/APJCP.2018.19.1.185>
- Song, M. K., Park, B. B., & Uhm, J. (2019). Understanding immune evasion and therapeutic targeting associated with PD-1/PD-L1 pathway in diffuse large B-cell lymphoma. *International Journal of Molecular Sciences*, 20(6), 1–16.
<https://doi.org/10.3390/ijms20061326>
- Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., ... Ladetto, M. (2015). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 26(Supplement 5), vii78–vii82. <https://doi.org/10.1093/annonc/mdv304>
- Tsai, A. G., & Lieber, M. R. (2010). Mechanisms of chromosomal rearrangement in the human genome. *BMC Genomics*, 11(SUPPL. 1), 1–9. <https://doi.org/10.1186/1471-2164-11-S1-S1>
- Wang, Y., Wang, H., Yao, H., Li, C., Fang, J., & Xu, J. (2018). Regulation of PD-L1 : Emerging Routes for Targeting Tumor Immune Evasion, 9(May), 1–13.
<https://doi.org/10.3389/fphar.2018.00536>
- Wd, T., Brambilla, E., Hermelink, H. K., Eds, H. C. C., Eble, J. N., Sauter, G., & Epstein, J. I. (2008). *World Health Organization Classification of Tumours This book and all other volumes of the series can be purchased : From all countri es. World Health Organization.*
- Xia, Y., Xu-Monette, Z. Y., Tzankov, A., Li, X., Manyam, G. C., Murty, V., ... Young, K. H. (2017). Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. *Leukemia*, 31(3), 625–636.
<https://doi.org/10.1038/leu.2016.243>
- Xing, W., Dresser, K., Zhang, R., Evens, A. M., Yu, H., Woda, B. A., & Chen, B. J. (2016). PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: Clinicopathologic features and prognostic implications. *Oncotarget*, 7(37), 59976–59986.
<https://doi.org/10.18632/oncotarget.11045>
- Yang, J., & Hu, G. (2019). Significance of PD - L1 in the diagnosis and treatment of B - cell malignant lymphoma, 3382–3386. <https://doi.org/10.3892/ol.2019.9982>
- Zhang, J., Medeiros, L. J., & Young, K. H. (2018). Cancer immunotherapy in diffuse large B-cell lymphoma. *Frontiers in Oncology*, 8(SEP), 1–12.
<https://doi.org/10.3389/fonc.2018.00351>

